BiotechTube

Mitapivat

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Pyruvate Kinase Deficiency

Conditions

Pyruvate Kinase Deficiency, Anemia, Hemolytic

Trial Timeline

Jul 6, 2023 → Aug 1, 2029

NCT ID
NCT05777993

About Mitapivat

Mitapivat is a approved stage product being developed by Agios Pharmaceuticals for Pyruvate Kinase Deficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05777993. Target conditions include Pyruvate Kinase Deficiency, Anemia, Hemolytic.

What happened to similar drugs?

0 of 5 similar drugs in Pyruvate Kinase Deficiency were approved

Approved (0) Terminated (0) Active (5)
🔄Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
🔄Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
🔄MitapivatAgios PharmaceuticalsPhase 3
🔄Placebo + AG-348Agios PharmaceuticalsPhase 3
🔄AG-348Agios PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
20
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT06286046Phase 2Recruiting
NCT07055243Phase 2Recruiting
NCT05777993ApprovedRecruiting
NCT05610657Phase 1Completed
NCT05031780Phase 2/3Active
NCT03853798Phase 3Completed

Competing Products

9 competing products in Pyruvate Kinase Deficiency

See all competitors
ProductCompanyStageHype Score
TriheptanoinUltragenyx PharmaceuticalPhase 1
30
Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
38
Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
38
MitapivatAgios PharmaceuticalsPhase 3
34
Placebo + AG-348Agios PharmaceuticalsPhase 3
34
AG-348Agios PharmaceuticalsPhase 3
34
AG-348Agios PharmaceuticalsPhase 2
29
RP-L301Rocket PharmaceuticalsPhase 1
19
RP-L301Rocket PharmaceuticalsPhase 2
32